PULM: Pulmatrix, Inc.
About
Pulmatrix, Inc. is a clinical stage biotechnology company, which engages in the development and discovery of novel inhaled therapeutics products. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov, and Robert S. Langer, Jr. in April 2003 and is headquartered in Framingham, MA.
Current Value
$6.421 Year Return
Current Value
$6.421 Year Return
Key Details
Market Cap
$23.16M
P/E Ratio
-2.4
1Y Stock Return
215.42%
1Y Revenue Growth
47.05%
Dividend Yield
0.00%
Price to Book
2.1
Strategies that include PULM
Stock's related to PULM
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| SYRS | -47.93% | $6.90M | -91.05% | 0.00% |
| PSFE | -37.98% | $1.23B | +94.24% | 0.00% |
| CACI | -32.09% | $10.30B | +36.68% | 0.00% |
| DOLE | -31.20% | $1.43B | +26.78% | 2.11% |
| LDOS | -29.51% | $21.90B | +47.47% | 0.92% |
| PLUS | -29.42% | $2.23B | +25.48% | 0.00% |
| CHMI | -27.73% | $84.44M | -32.41% | 22.22% |
| MMS | -27.24% | $4.47B | -14.64% | 1.62% |
| HALO | -27.20% | $6.18B | +21.14% | 0.00% |
| INSG | -26.86% | $183.80M | +395.96% | 0.00% |
| ZI | -26.58% | $3.90B | -22.77% | 0.00% |
| SAIC | -25.38% | $6.16B | -8.56% | 1.19% |
| BLFS | -25.07% | $1.26B | +96.75% | 0.00% |
| QTRX | -24.83% | $481.27M | -49.11% | 0.00% |
| KBR | -24.22% | $8.14B | +14.99% | 0.96% |
| SGRY | -24.06% | $3.03B | -32.95% | 0.00% |
| SYM | -23.91% | $2.69B | -53.93% | 0.00% |
| BAH | -23.72% | $19.00B | +13.34% | 1.37% |
| DOX | -23.72% | $10.01B | +2.73% | 2.14% |
| CART | -23.71% | $11.18B | +78.25% | 0.00% |
ETF's related to PULM
News
Yahoo
Pulmatrix, Inc. ("Pulmatrix") (Nasdaq: PULM), a clinical-stage biopharmaceutical company, today announced a merger agreement with Cullgen Inc. ("Cullgen"), a privately-held, clinical-stage biopharmaceutical company applying its proprietary targeted protein degradation uSMITE™ platform to discover and advance therapeutics for the treatment of cancer and other diseases. Cullgen utilizes its proprietary technology platform, uSMITE™, featuring novel E3 ligands, to build the next generation of target
Yahoo
Pulmatrix ( NASDAQ:PULM ) Third Quarter 2024 Results Key Financial Results Revenue: US$366.0k (down 79% from 3Q 2023...
Yahoo
Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious central nervous system and pulmonary disease using its patented dry powder inhalation iSPERSE™ technology, today announced third quarter financial results for 2024 and provided a corporate update on its clinical assets.
Yahoo
Pulmatrix ( NASDAQ:PULM ) Second Quarter 2024 Results Key Financial Results Revenue: US$1.55m (down 16% from 2Q 2023...
Yahoo
Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious central nervous system and pulmonary disease using its patented dry powder inhalation iSPERSE™ technology, today announced second quarter financial results for 2024 and provided a corporate update on its clinical assets.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.